CAPR News and Press, Capricor Therapeutics Inc. From 01/25/23

-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential Disease Modification in Duchenne Muscular Dystrophy (DMD)- -Capricor to...

-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therap...

-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative ce...

Capricor Therapeutics, Inc. (CAPR) Q3 2022 Results Conference Call November 10, 2022 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Alan Leong - BioWatch News Aydin Huseynov - Ladenburg Bria...

Capricor Therapeutics press release ( NASDAQ: CAPR ): Q3 GAAP EPS of -$0.26 beats by $0.05 . Revenue of $1.59M beats by $1.45M . For further details see: Capricor Therapeutics GAAP EPS of -$0.26 beats by $0.05, revenue of $1.59M beats by $1.45M

-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients at...

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial resu...

SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Com...

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Co...

Shares of Capricor Therapeutics ( NASDAQ: CAPR ) on Thursday gained 16% to $5.24, after the clinical-stage biotech announced an update on its lead drug candidate and reported Q2 results. San Diego, Calif.-based CAPR's lead candidate is a cardiac cell therapy called CAP...